Study: FDG PET/CT could aid in predicting osteosarcoma outcomes

08/28/2013 | MolecularImaging.net

A study in the Journal of Nuclear Medicine suggests that using FDG PET/CT to measure metabolic tumor volume may predict survival of patients with osteosarcoma of the extremities and be useful in clinical decision making. Researchers analyzed FDG PET/CT scans of 83 patients who had been treated with chemotherapy and surgery, finding that the MTV using a 2.0 uptake value threshold predicted metastasis risk and poor therapeutic response.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX